Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425162 | 1.00 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL24026373 | 1.00 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182300 | 0.88 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19180965 | 0.87 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19180964 | 0.87 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL26245461 | 0.86 | ERBB2 (0.76) | ERBB2EGFR | |
| SCHEMBL19181013 | 0.85 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL29434938 | 0.85 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL29926978 | 0.85 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181012 | 0.85 | ERBB2 (1.00) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3909584-B1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-12-13 | — | — | EP | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230285397-A1 | EGFR INHIBITOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-4183395-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2023-05-24 | — | — | EP | disclosed |
| WO-2022014640-A1 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | 大鵬薬品工業株式会社 | 2022-01-20 | — | — | WO | disclosed |
| WO-2022014639-A1 | EGFR INHIBITOR | 大鵬薬品工業株式会社 | 2022-01-20 | — | — | WO | disclosed |
| EP-3909584-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-11-17 | — | — | EP | disclosed |
| US-11078207-B2 | Substituted pyrrolo[2,3-d]pyrimidines as HER2 inhibitors | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-03 | — | — | US | disclosed |
| US-20210024530-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
| WO-2020145374-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2020-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024530-A1 | PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, EGFR, ERBB4 | ERBB2 1/4885EGFR 2/4885 |
| US-11078207-B2 | Substituted pyrrolo[2,3-d]pyrimidines as HER2 inhibitors | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885 |
| US-20230285397-A1 | EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | ERBB2 2/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.